Oncology
2 drugs are in development for Myasthenia Gravis, Generalized.
- Companies
- 1
- Clinical trials
- 9
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Myasthenia Gravis, Generalized pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(2)
| Drug | Company |
|---|---|
| zilucoplan | RA PHARMACEUTICALS, INC. (RARX) |
| zilucoplan xr | RA PHARMACEUTICALS, INC. (RARX) |
About this indication
Myasthenia Gravis, Generalized context
Oncology·MeSH: Myasthenia Gravis (D009157)
Narrower concept of MeSH descriptor Myasthenia Gravis
Incidence
1.7 / 100K/yr
Frequently asked questions
How many drugs are in development for Myasthenia Gravis, Generalized?
BioSniper tracks 2 drugs in development for Myasthenia Gravis, Generalized across 1 company.
How many clinical trials target Myasthenia Gravis, Generalized?
There are 9 clinical trials targeting Myasthenia Gravis, Generalized tracked by BioSniper.